Financhill
Buy
56

VSTM Quote, Financials, Valuation and Earnings

Last price:
$7.00
Seasonality move :
11.51%
Day range:
$6.90 - $7.31
52-week range:
$2.10 - $13.52
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
29.09x
Volume:
577.3K
Avg. volume:
741.6K
1-year change:
-34.27%
Market cap:
$321.8M
Revenue:
--
EPS (TTM):
-$3.20

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
VSTM
Verastem
$150K -$0.74 -- -28.48% $12.57
ACAD
ACADIA Pharmaceuticals
$272.1M $0.22 16.28% -91.94% $24.85
APLT
Applied Therapeutics
$100K -$0.18 -76.55% -43.43% $5.50
CTMX
CytomX Therapeutics
$13M -$0.11 -31.21% -39.59% $4.94
RVPH
Reviva Pharmaceuticals Holdings
-- -$0.22 -- -30.3% $12.14
SPRO
Spero Therapeutics
$6.2M -$0.31 -100% -505.55% $5.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
VSTM
Verastem
$7.23 $12.57 $321.8M -- $0.00 0% --
ACAD
ACADIA Pharmaceuticals
$17.20 $24.85 $2.9B 12.65x $0.00 0% 2.99x
APLT
Applied Therapeutics
$0.55 $5.50 $63.6M -- $0.00 0% --
CTMX
CytomX Therapeutics
$0.63 $4.94 $50.7M 1.62x $0.00 0% 0.39x
RVPH
Reviva Pharmaceuticals Holdings
$1.10 $12.14 $36.8M -- $0.00 0% --
SPRO
Spero Therapeutics
$0.77 $5.00 $42M 9.64x $0.00 0% 0.46x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
VSTM
Verastem
50.52% 0.070 40.34% 3.10x
ACAD
ACADIA Pharmaceuticals
-- -0.163 -- 2.18x
APLT
Applied Therapeutics
-- 0.844 -- 1.00x
CTMX
CytomX Therapeutics
-- 1.655 -- 1.21x
RVPH
Reviva Pharmaceuticals Holdings
-- -0.897 -- --
SPRO
Spero Therapeutics
-- 1.066 -- 2.64x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
VSTM
Verastem
-- -$37M -78.01% -120.71% -71.18% -$23.8M
ACAD
ACADIA Pharmaceuticals
$237.8M $7M 41.59% 41.59% 2.69% $39.9M
APLT
Applied Therapeutics
-- -$29.7M -790.52% -797.82% -24379.51% -$23.3M
CTMX
CytomX Therapeutics
-- $17.7M -- -- 46.41% -$20M
RVPH
Reviva Pharmaceuticals Holdings
-- -$8.5M -- -- -- -$4.2M
SPRO
Spero Therapeutics
-- -$18.6M 4.36% 4.36% -237.79% $12.8M

Verastem vs. Competitors

  • Which has Higher Returns VSTM or ACAD?

    ACADIA Pharmaceuticals has a net margin of -82.56% compared to Verastem's net margin of 55.37%. Verastem's return on equity of -120.71% beat ACADIA Pharmaceuticals's return on equity of 41.59%.

    Company Gross Margin Earnings Per Share Invested Capital
    VSTM
    Verastem
    -- -$0.60 $80.9M
    ACAD
    ACADIA Pharmaceuticals
    91.6% $0.86 $732.8M
  • What do Analysts Say About VSTM or ACAD?

    Verastem has a consensus price target of $12.57, signalling upside risk potential of 73.88%. On the other hand ACADIA Pharmaceuticals has an analysts' consensus of $24.85 which suggests that it could grow by 44.48%. Given that Verastem has higher upside potential than ACADIA Pharmaceuticals, analysts believe Verastem is more attractive than ACADIA Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    VSTM
    Verastem
    6 0 0
    ACAD
    ACADIA Pharmaceuticals
    6 7 0
  • Is VSTM or ACAD More Risky?

    Verastem has a beta of 0.605, which suggesting that the stock is 39.46% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals has a beta of 0.426, suggesting its less volatile than the S&P 500 by 57.361%.

  • Which is a Better Dividend Stock VSTM or ACAD?

    Verastem has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem pays -- of its earnings as a dividend. ACADIA Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VSTM or ACAD?

    Verastem quarterly revenues are $10M, which are smaller than ACADIA Pharmaceuticals quarterly revenues of $259.6M. Verastem's net income of -$24M is lower than ACADIA Pharmaceuticals's net income of $143.7M. Notably, Verastem's price-to-earnings ratio is -- while ACADIA Pharmaceuticals's PE ratio is 12.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem is -- versus 2.99x for ACADIA Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VSTM
    Verastem
    -- -- $10M -$24M
    ACAD
    ACADIA Pharmaceuticals
    2.99x 12.65x $259.6M $143.7M
  • Which has Higher Returns VSTM or APLT?

    Applied Therapeutics has a net margin of -82.56% compared to Verastem's net margin of -56222.13%. Verastem's return on equity of -120.71% beat Applied Therapeutics's return on equity of -797.82%.

    Company Gross Margin Earnings Per Share Invested Capital
    VSTM
    Verastem
    -- -$0.60 $80.9M
    APLT
    Applied Therapeutics
    -- -$0.48 $5.9M
  • What do Analysts Say About VSTM or APLT?

    Verastem has a consensus price target of $12.57, signalling upside risk potential of 73.88%. On the other hand Applied Therapeutics has an analysts' consensus of $5.50 which suggests that it could grow by 906.59%. Given that Applied Therapeutics has higher upside potential than Verastem, analysts believe Applied Therapeutics is more attractive than Verastem.

    Company Buy Ratings Hold Ratings Sell Ratings
    VSTM
    Verastem
    6 0 0
    APLT
    Applied Therapeutics
    2 3 0
  • Is VSTM or APLT More Risky?

    Verastem has a beta of 0.605, which suggesting that the stock is 39.46% less volatile than S&P 500. In comparison Applied Therapeutics has a beta of 1.881, suggesting its more volatile than the S&P 500 by 88.052%.

  • Which is a Better Dividend Stock VSTM or APLT?

    Verastem has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Applied Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem pays -- of its earnings as a dividend. Applied Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VSTM or APLT?

    Verastem quarterly revenues are $10M, which are larger than Applied Therapeutics quarterly revenues of $122K. Verastem's net income of -$24M is higher than Applied Therapeutics's net income of -$68.6M. Notably, Verastem's price-to-earnings ratio is -- while Applied Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem is -- versus -- for Applied Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VSTM
    Verastem
    -- -- $10M -$24M
    APLT
    Applied Therapeutics
    -- -- $122K -$68.6M
  • Which has Higher Returns VSTM or CTMX?

    CytomX Therapeutics has a net margin of -82.56% compared to Verastem's net margin of 49.55%. Verastem's return on equity of -120.71% beat CytomX Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    VSTM
    Verastem
    -- -$0.60 $80.9M
    CTMX
    CytomX Therapeutics
    -- $0.23 -$456K
  • What do Analysts Say About VSTM or CTMX?

    Verastem has a consensus price target of $12.57, signalling upside risk potential of 73.88%. On the other hand CytomX Therapeutics has an analysts' consensus of $4.94 which suggests that it could grow by 680.14%. Given that CytomX Therapeutics has higher upside potential than Verastem, analysts believe CytomX Therapeutics is more attractive than Verastem.

    Company Buy Ratings Hold Ratings Sell Ratings
    VSTM
    Verastem
    6 0 0
    CTMX
    CytomX Therapeutics
    2 2 0
  • Is VSTM or CTMX More Risky?

    Verastem has a beta of 0.605, which suggesting that the stock is 39.46% less volatile than S&P 500. In comparison CytomX Therapeutics has a beta of 1.045, suggesting its more volatile than the S&P 500 by 4.544%.

  • Which is a Better Dividend Stock VSTM or CTMX?

    Verastem has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CytomX Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem pays -- of its earnings as a dividend. CytomX Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VSTM or CTMX?

    Verastem quarterly revenues are $10M, which are smaller than CytomX Therapeutics quarterly revenues of $38.1M. Verastem's net income of -$24M is lower than CytomX Therapeutics's net income of $18.9M. Notably, Verastem's price-to-earnings ratio is -- while CytomX Therapeutics's PE ratio is 1.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem is -- versus 0.39x for CytomX Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VSTM
    Verastem
    -- -- $10M -$24M
    CTMX
    CytomX Therapeutics
    0.39x 1.62x $38.1M $18.9M
  • Which has Higher Returns VSTM or RVPH?

    Reviva Pharmaceuticals Holdings has a net margin of -82.56% compared to Verastem's net margin of --. Verastem's return on equity of -120.71% beat Reviva Pharmaceuticals Holdings's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    VSTM
    Verastem
    -- -$0.60 $80.9M
    RVPH
    Reviva Pharmaceuticals Holdings
    -- -$0.25 --
  • What do Analysts Say About VSTM or RVPH?

    Verastem has a consensus price target of $12.57, signalling upside risk potential of 73.88%. On the other hand Reviva Pharmaceuticals Holdings has an analysts' consensus of $12.14 which suggests that it could grow by 1003.9%. Given that Reviva Pharmaceuticals Holdings has higher upside potential than Verastem, analysts believe Reviva Pharmaceuticals Holdings is more attractive than Verastem.

    Company Buy Ratings Hold Ratings Sell Ratings
    VSTM
    Verastem
    6 0 0
    RVPH
    Reviva Pharmaceuticals Holdings
    3 0 0
  • Is VSTM or RVPH More Risky?

    Verastem has a beta of 0.605, which suggesting that the stock is 39.46% less volatile than S&P 500. In comparison Reviva Pharmaceuticals Holdings has a beta of -0.095, suggesting its less volatile than the S&P 500 by 109.539%.

  • Which is a Better Dividend Stock VSTM or RVPH?

    Verastem has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Reviva Pharmaceuticals Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem pays -- of its earnings as a dividend. Reviva Pharmaceuticals Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VSTM or RVPH?

    Verastem quarterly revenues are $10M, which are larger than Reviva Pharmaceuticals Holdings quarterly revenues of --. Verastem's net income of -$24M is lower than Reviva Pharmaceuticals Holdings's net income of -$8.4M. Notably, Verastem's price-to-earnings ratio is -- while Reviva Pharmaceuticals Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem is -- versus -- for Reviva Pharmaceuticals Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VSTM
    Verastem
    -- -- $10M -$24M
    RVPH
    Reviva Pharmaceuticals Holdings
    -- -- -- -$8.4M
  • Which has Higher Returns VSTM or SPRO?

    Spero Therapeutics has a net margin of -82.56% compared to Verastem's net margin of -219.3%. Verastem's return on equity of -120.71% beat Spero Therapeutics's return on equity of 4.36%.

    Company Gross Margin Earnings Per Share Invested Capital
    VSTM
    Verastem
    -- -$0.60 $80.9M
    SPRO
    Spero Therapeutics
    -- -$0.32 $65.5M
  • What do Analysts Say About VSTM or SPRO?

    Verastem has a consensus price target of $12.57, signalling upside risk potential of 73.88%. On the other hand Spero Therapeutics has an analysts' consensus of $5.00 which suggests that it could grow by 548.59%. Given that Spero Therapeutics has higher upside potential than Verastem, analysts believe Spero Therapeutics is more attractive than Verastem.

    Company Buy Ratings Hold Ratings Sell Ratings
    VSTM
    Verastem
    6 0 0
    SPRO
    Spero Therapeutics
    0 2 0
  • Is VSTM or SPRO More Risky?

    Verastem has a beta of 0.605, which suggesting that the stock is 39.46% less volatile than S&P 500. In comparison Spero Therapeutics has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.497%.

  • Which is a Better Dividend Stock VSTM or SPRO?

    Verastem has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spero Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem pays -- of its earnings as a dividend. Spero Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VSTM or SPRO?

    Verastem quarterly revenues are $10M, which are larger than Spero Therapeutics quarterly revenues of $7.8M. Verastem's net income of -$24M is lower than Spero Therapeutics's net income of -$17.1M. Notably, Verastem's price-to-earnings ratio is -- while Spero Therapeutics's PE ratio is 9.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem is -- versus 0.46x for Spero Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VSTM
    Verastem
    -- -- $10M -$24M
    SPRO
    Spero Therapeutics
    0.46x 9.64x $7.8M -$17.1M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Is Ford Stock Undervalued Amid the EV Transition?
Is Ford Stock Undervalued Amid the EV Transition?

There is a lot going on in the electric vehicle…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Sell
48
SMTC alert for Mar 18

Semtech [SMTC] is down 1.29% over the past day.

Buy
67
PLPC alert for Mar 18

Preformed Line Products [PLPC] is up 0.96% over the past day.

Buy
58
NUTX alert for Mar 18

Nutex Health [NUTX] is down 3.64% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock